M
Michele Caraglia
Researcher at Seconda Università degli Studi di Napoli
Publications - 562
Citations - 24508
Michele Caraglia is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 67, co-authored 525 publications receiving 20615 citations. Previous affiliations of Michele Caraglia include Temple University & Magna Græcia University.
Papers
More filters
Journal ArticleDOI
Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer : in vitro and in vivo studies
Giovanni Vitale,Giovanni Lupoli,Rosario Guarrasi,Annamaria Colao,Alessandra Dicitore,Germano Gaudenzi,Gabriella Misso,Maria Castellano,Raffaele Addeo,Gaetano Facchini,Salvatore Del Prete,Michele Caraglia +11 more
TL;DR: Both in vitro and in vivo evidence suggests that the combination of LAN and IL-2 may have a role in the management of advanced and symptomatic MTC, although these preliminary data require further validation in larger randomized trials.
Journal ArticleDOI
Current treatment of cutaneous squamous cancer and molecular strategies for its sensitization to new target-based drugs.
Renato Franco,Gianfranco Nicoletti,Angela Lombardi,Marina Di Domenico,Gerardo Botti,Federica Zito Marino,Michele Caraglia +6 more
TL;DR: It is hypothesized that SCC cells can develop survival and resistance mechanisms to MTAs and the detection of these mechanisms could be useful in designing strategies able to overcome the latter and to potentiate the anticancer activity of MTAs.
Journal ArticleDOI
Analysis of interaction partners for eukaryotic translation elongation factor 1A M-domain by functional proteomics.
Annalisa Lamberti,Carmen Sanges,Angela Chambery,Nunzia Migliaccio,Francesco Rosso,Antimo Di Maro,Ferdinando Papale,Monica Marra,Augusto Parente,Michele Caraglia,Alberto Abbruzzese,Paolo Arcari +11 more
TL;DR: Interestingly, a co-localization of SORBS2 and eEF1A was evidenced at level of plasma membrane, thus suggesting the involvement of e EF1A1 in novel key signal transduction complexes.
Journal ArticleDOI
Oxidative stress in chronic lymphocytic leukemia: still a matter of debate.
Giovanni D'Arena,Elisa Seneca,Ilaria Migliaccio,Vincenzo De Feo,Aldo Giudice,Francesco La Rocca,Mario Capunzo,Gioacchino Calapai,Agostino Festa,Michele Caraglia,Pellegrino Musto,Eugenio Luigi Iorio,Vitalba Ruggieri +12 more
TL;DR: Interestingly, OS evaluation in CLL patients, at diagnosis, seems to have a prognostic significance, thus getting new insights in the biological comprehension of the disease with potential therapeutic implications.
Journal ArticleDOI
The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity.
Mariarosaria Boccellino,Lucio Quagliuolo,Concetta Alaia,Anna Grimaldi,Raffaele Addeo,Giovanni Francesco Nicoletti,Richard Eric Kast,Michele Caraglia +7 more
TL;DR: Experimental evidence is reported that shows the use of dapsone to improve quality of life in erlotinib-treated patients by ameliorating rash as well as short-circuiting a growth-enhancing aspect of erlot inib based on increased interleukin-8 secretion.